Patients with metastatic disease receiving aromatase inhibitor plus palbociclib and with a rising ESR1 mutation may benefit from early switch to fulvestrant plus palbociclib.
(BPT) - Everyone has been touched by cancer in some way, whether it s a friend or family member facing a diagnosis, or their own worry about susceptibility to the disease.